M A Meheissen, S M Hendawy, F S Shabaan, A M Elmenshawy, R A Harfoush
{"title":"重症监护病房肺炎克雷伯菌和大肠杆菌临床分离株的粘菌素耐药性和异源耐药性。","authors":"M A Meheissen, S M Hendawy, F S Shabaan, A M Elmenshawy, R A Harfoush","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Colistin resistance poses a serious clinical problem. This study aims to investigate the presence of plasmid-mediated resistance and heteroresistance among Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) clinical isolates at intensive care units of Main Alexandria University Hospital.</p><p><strong>Material and methods: </strong>Seventy colistin-resistant and 30 colistin-susceptible K. pneumoniae and E. coli isolates constituted the material of the study. The rapid polymyxin NP (Nordmann Poirel) test was performed. Heteroresistance in colistin-susceptible isolates was investigated by population analysis profile. mcr-1 and mcr-2 genes were amplified by polymerase chain reaction (PCR).</p><p><strong>Results: </strong>The rapid polymyxin NP test showed 100% concordance with the results of BMD (broth microdilution method). Heteroresistance to colistin was detected in 23.3% of colistin-susceptible K. pneumoniae isolates. All colistin-resistant isolates were negative for mcr-1 and mcr-2 genes.</p><p><strong>Conclusions: </strong>The rapid polymyxin NP test is a reliable screening tool for colistin resistance, but not for heteroresistance. Other colistin resistance mechanisms should be investigated.</p>","PeriodicalId":54374,"journal":{"name":"Epidemiologie Mikrobiologie Imunologie","volume":"71 2","pages":"86-92"},"PeriodicalIF":0.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Colistin resistance and heteroresistance in Klebsiella pneumoniae & Escherichia coli clinical isolates from intensive care units.\",\"authors\":\"M A Meheissen, S M Hendawy, F S Shabaan, A M Elmenshawy, R A Harfoush\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Colistin resistance poses a serious clinical problem. This study aims to investigate the presence of plasmid-mediated resistance and heteroresistance among Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) clinical isolates at intensive care units of Main Alexandria University Hospital.</p><p><strong>Material and methods: </strong>Seventy colistin-resistant and 30 colistin-susceptible K. pneumoniae and E. coli isolates constituted the material of the study. The rapid polymyxin NP (Nordmann Poirel) test was performed. Heteroresistance in colistin-susceptible isolates was investigated by population analysis profile. mcr-1 and mcr-2 genes were amplified by polymerase chain reaction (PCR).</p><p><strong>Results: </strong>The rapid polymyxin NP test showed 100% concordance with the results of BMD (broth microdilution method). Heteroresistance to colistin was detected in 23.3% of colistin-susceptible K. pneumoniae isolates. All colistin-resistant isolates were negative for mcr-1 and mcr-2 genes.</p><p><strong>Conclusions: </strong>The rapid polymyxin NP test is a reliable screening tool for colistin resistance, but not for heteroresistance. Other colistin resistance mechanisms should be investigated.</p>\",\"PeriodicalId\":54374,\"journal\":{\"name\":\"Epidemiologie Mikrobiologie Imunologie\",\"volume\":\"71 2\",\"pages\":\"86-92\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiologie Mikrobiologie Imunologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiologie Mikrobiologie Imunologie","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Colistin resistance and heteroresistance in Klebsiella pneumoniae & Escherichia coli clinical isolates from intensive care units.
Aim: Colistin resistance poses a serious clinical problem. This study aims to investigate the presence of plasmid-mediated resistance and heteroresistance among Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) clinical isolates at intensive care units of Main Alexandria University Hospital.
Material and methods: Seventy colistin-resistant and 30 colistin-susceptible K. pneumoniae and E. coli isolates constituted the material of the study. The rapid polymyxin NP (Nordmann Poirel) test was performed. Heteroresistance in colistin-susceptible isolates was investigated by population analysis profile. mcr-1 and mcr-2 genes were amplified by polymerase chain reaction (PCR).
Results: The rapid polymyxin NP test showed 100% concordance with the results of BMD (broth microdilution method). Heteroresistance to colistin was detected in 23.3% of colistin-susceptible K. pneumoniae isolates. All colistin-resistant isolates were negative for mcr-1 and mcr-2 genes.
Conclusions: The rapid polymyxin NP test is a reliable screening tool for colistin resistance, but not for heteroresistance. Other colistin resistance mechanisms should be investigated.
期刊介绍:
The journal publishes original papers, information from practice, reviews on epidemiological and microbiological subjects. Sufficient space is devoted to diagnostic methods from medical microbiology, parasitology, immunology, and to general aspects and discussions pertaining to preventive medicine. It also brings translations and book reviews useful for medical doctors and research workers and professionals in public health.